MDK’s role in angiogenesis and therapy resistance has been confirmed through angiogenesis-related analyses associated with prognosis and tumor immune microenvironment, as well as single-cell RNA sequencing studies identifying molecular biomarkers predicting progression to CDK4/6 inhibition [35, 36]. Here, CDK4 is linked to neoplasm.